Resources Repository
-
OrganizationWeb Portal 2024Center for the Evaluation of Value and Risk in Health (CEVR)
CEVR, the Center for the Evaluation of Value and Risk in Health, at Tufts Medical …
CEVR, the Center for the Evaluation of Value and Risk in Health, at Tufts Medical Center was established in 2005 and analyzes the benefits, risks and costs of strategies to improve health and health care. CEVR undertakes projects to determine the cost-effectiveness of health care interventions, including customized analyses for government agencies, private foundations and industry groups. CEVR has developed and maintains two internationally-known databases for health care stakeholders: the Cost-Effectiveness Analysis Registry and the National Coverage Determinations…
Technology Assessment | Health/Medicine | North America | Health Systems | Health Outcomes | Cost-Effectiveness Analysis -
ReviewPublication 2015Economic Evaluation of Diet and Physical Activity to Prevent Type 2 Diabetes: Systematic Review
Studies indicate that combined diet and physical activity promotion programs can prevent type 2 diabetes …
Studies indicate that combined diet and physical activity promotion programs can prevent type 2 diabetes among persons at increased risk. This paper systematically evaluates the evidence on cost, cost-effectiveness, and cost–benefit estimates of diet and physical activity promotion programs. English-language studies from high-income countries that provided data on cost, cost-effectiveness, or cost–benefit ratios of diet and physical activity promotion programs with at least 2 sessions over at least 3 months delivered to persons at increased risk…
Evidence Synthesis | Health/Medicine | North America | Health Systems | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Social Determinants | Food/Agriculture | Europe | Asia & Pacific -
ReviewPublication 2013Role of Health Economic Analyses in Vaccine Decision Making
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in …
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in the US, cost effectiveness became a topic of discussion when a vaccine was being considered for universal use by the US Advisory Committee on Immunization practices (ACIP). In 2008, the ACIP began using formal criteria for the presentation of such data and their inclusion in ACIP discussions. More recently, the U.S. Institute of Medicine has recommended that health economic considerations play a…
Priority Setting/Ethics | Health/Medicine | North America | Health Systems | Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance